jun 6, 2018: 3 p.m. - 4 p.m.
Room 206AB, Level 2
While many patients have benefited from the advent of immuno-oncology agents, there are still a significant number who do not respond to I/O therapy, or experience relapse after initial success. There are a number of approaches being studied to uncover more pathways to address the needs of patients, and to understand more about the mechanisms of resistance. This discussion will explore how research is moving upstream in the immune system to leverage new pathways, preliminary research on mechanisms of resistance, and the importance of recognizing pathways and molecular signatures governing T-cell exhaustion to overcome resistance.